# ðŸ”¬ Inebilizumab Path Analysis Report

## Drug Profile

| Property | Value |
|----------|-------|
| **Drug ID** | DB12530 |
| **Drug Name** | Inebilizumab |
| **Trade Name** | Uplizna |
| **Type** | Humanized monoclonal antibody |
| **Target** | CD19 (B-cell surface marker) |
| **Mechanism** | Depletes CD19+ B cells via antibody-dependent cellular cytotoxicity (ADCC) |
| **FDA Approved Indication** | Neuromyelitis optica spectrum disorder (NMOSD) |

---

## Path Statistics

| Metric | Value |
|--------|-------|
| **Total Paths** | 1600 |
| **Unique Diseases Reachable** | 420 |
| **Mean Attention Score** | 0.6062 |
| **Attention Range** | 0.4768 - 0.7496 |

---

## Top 20 Paths with Detailed Explanations

### Path 1: psychologic dyspareunia

**Path Visualization:**
```
[Inebilizumab] --(0.756)--> [Conjugated estrogens] --(0.554)--> [psychologic dyspareunia]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6552
- **Combined Score:** 0.4633
- **Edge Attention Scores:** 0.756 â†’ 0.554

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Conjugated estrogens** in the TxGNN embedding space (attention: 0.756)
2. **Conjugated estrogens** has a known association with **psychologic dyspareunia**
3. **Inference:** Since Inebilizumab and Conjugated estrogens share similar properties in the learned embedding space, Inebilizumab may also be relevant for psychologic dyspareunia

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Conjugated estrogens. If Conjugated estrogens is approved for or has been studied in psychologic dyspareunia, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 2: obsolete susceptibility to ischemic stroke

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.539)--> [obsolete susceptibility to ischemic stroke]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6384
- **Combined Score:** 0.4515
- **Edge Attention Scores:** 0.738 â†’ 0.539

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **obsolete susceptibility to ischemic stroke**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for obsolete susceptibility to ischemic stroke

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in obsolete susceptibility to ischemic stroke, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 3: neurotic disorder

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.538)--> [neurotic disorder]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6383
- **Combined Score:** 0.4514
- **Edge Attention Scores:** 0.738 â†’ 0.538

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **neurotic disorder**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for neurotic disorder

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in neurotic disorder, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 4: cervical carcinosarcoma

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.538)--> [cervical carcinosarcoma]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6383
- **Combined Score:** 0.4513
- **Edge Attention Scores:** 0.738 â†’ 0.538

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **cervical carcinosarcoma**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for cervical carcinosarcoma

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in cervical carcinosarcoma, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 5: migraine with or without aura, susceptibility to

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.538)--> [migraine with or without aura, susceptibility to]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6380
- **Combined Score:** 0.4511
- **Edge Attention Scores:** 0.738 â†’ 0.538

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **migraine with or without aura, susceptibility to**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for migraine with or without aura, susceptibility to

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in migraine with or without aura, susceptibility to, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 6: cerebral infarction

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.537)--> [cerebral infarction]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6378
- **Combined Score:** 0.4510
- **Edge Attention Scores:** 0.738 â†’ 0.537

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **cerebral infarction**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for cerebral infarction

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in cerebral infarction, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 7: biliary tract disease

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.537)--> [biliary tract disease]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6374
- **Combined Score:** 0.4507
- **Edge Attention Scores:** 0.738 â†’ 0.537

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **biliary tract disease**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for biliary tract disease

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in biliary tract disease, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 8: obstructive jaundice

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.536)--> [obstructive jaundice]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6369
- **Combined Score:** 0.4504
- **Edge Attention Scores:** 0.738 â†’ 0.536

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **obstructive jaundice**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for obstructive jaundice

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in obstructive jaundice, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 9: endometrium neoplasm

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.535)--> [endometrium neoplasm]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6366
- **Combined Score:** 0.4502
- **Edge Attention Scores:** 0.738 â†’ 0.535

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **endometrium neoplasm**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for endometrium neoplasm

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in endometrium neoplasm, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 10: stroke disorder

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.535)--> [stroke disorder]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6366
- **Combined Score:** 0.4502
- **Edge Attention Scores:** 0.738 â†’ 0.535

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **stroke disorder**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for stroke disorder

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in stroke disorder, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 11: coronary artery disease

**Path Visualization:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.533)--> [coronary artery disease]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6359
- **Combined Score:** 0.4496
- **Edge Attention Scores:** 0.738 â†’ 0.533

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Mestranol** in the TxGNN embedding space (attention: 0.738)
2. **Mestranol** has a known association with **coronary artery disease**
3. **Inference:** Since Inebilizumab and Mestranol share similar properties in the learned embedding space, Inebilizumab may also be relevant for coronary artery disease

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Mestranol. If Mestranol is approved for or has been studied in coronary artery disease, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 12: ovarian carcinosarcoma

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.540)--> [ovarian carcinosarcoma]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6341
- **Combined Score:** 0.4483
- **Edge Attention Scores:** 0.728 â†’ 0.540

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **ovarian carcinosarcoma**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for ovarian carcinosarcoma

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in ovarian carcinosarcoma, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 13: uterine corpus leiomyoma

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.538)--> [uterine corpus leiomyoma]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6330
- **Combined Score:** 0.4476
- **Edge Attention Scores:** 0.728 â†’ 0.538

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **uterine corpus leiomyoma**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for uterine corpus leiomyoma

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in uterine corpus leiomyoma, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 14: maligant granulosa cell tumor of ovary

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.537)--> [maligant granulosa cell tumor of ovary]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6325
- **Combined Score:** 0.4473
- **Edge Attention Scores:** 0.728 â†’ 0.537

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **maligant granulosa cell tumor of ovary**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for maligant granulosa cell tumor of ovary

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in maligant granulosa cell tumor of ovary, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 15: cerebral infarction

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.537)--> [cerebral infarction]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6323
- **Combined Score:** 0.4471
- **Edge Attention Scores:** 0.728 â†’ 0.537

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **cerebral infarction**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for cerebral infarction

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in cerebral infarction, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 16: intrinsic asthma

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.536)--> [intrinsic asthma]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6317
- **Combined Score:** 0.4467
- **Edge Attention Scores:** 0.728 â†’ 0.536

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **intrinsic asthma**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for intrinsic asthma

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in intrinsic asthma, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 17: migraine with or without aura, susceptibility to

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.535)--> [migraine with or without aura, susceptibility to]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6314
- **Combined Score:** 0.4465
- **Edge Attention Scores:** 0.728 â†’ 0.535

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **migraine with or without aura, susceptibility to**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for migraine with or without aura, susceptibility to

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in migraine with or without aura, susceptibility to, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 18: endometrium neoplasm

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.535)--> [endometrium neoplasm]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6315
- **Combined Score:** 0.4465
- **Edge Attention Scores:** 0.728 â†’ 0.535

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **endometrium neoplasm**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for endometrium neoplasm

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in endometrium neoplasm, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 19: obsolete susceptibility to ischemic stroke

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.534)--> [obsolete susceptibility to ischemic stroke]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6311
- **Combined Score:** 0.4463
- **Edge Attention Scores:** 0.728 â†’ 0.534

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **obsolete susceptibility to ischemic stroke**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for obsolete susceptibility to ischemic stroke

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in obsolete susceptibility to ischemic stroke, this provides a rationale for investigating Inebilizumab in similar contexts.

---

### Path 20: ovarian small cell carcinoma

**Path Visualization:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.534)--> [ovarian small cell carcinoma]
```

**Path Details:**
- **Hops:** 2
- **Average Attention:** 0.6310
- **Combined Score:** 0.4462
- **Edge Attention Scores:** 0.728 â†’ 0.534

**Node Types:** drug â†’ drug â†’ disease

**Biological Interpretation:**

This is a **Drug Similarity Path**. The interpretation is:

1. **Inebilizumab** is semantically similar to **Chlorotrianisene** in the TxGNN embedding space (attention: 0.728)
2. **Chlorotrianisene** has a known association with **ovarian small cell carcinoma**
3. **Inference:** Since Inebilizumab and Chlorotrianisene share similar properties in the learned embedding space, Inebilizumab may also be relevant for ovarian small cell carcinoma

**Clinical Relevance:** This path suggests that Inebilizumab may share therapeutic or mechanistic properties with Chlorotrianisene. If Chlorotrianisene is approved for or has been studied in ovarian small cell carcinoma, this provides a rationale for investigating Inebilizumab in similar contexts.

---

## Path Type Summary

### Drug â†’ Drug â†’ Disease (Drug Similarity Paths)

These paths indicate that Inebilizumab shares embedding space similarity with other drugs that treat the target disease. Key intermediate drugs include:


#### Via Chlorotrianisene (Similarity: 0.728)
- **Number of disease connections:** 50
- **Top diseases:** ovarian carcinosarcoma, uterine corpus leiomyoma, maligant granulosa cell tumor of ovary, cerebral infarction, intrinsic asthma

#### Via Mestranol (Similarity: 0.738)
- **Number of disease connections:** 39
- **Top diseases:** obsolete susceptibility to ischemic stroke, neurotic disorder, cervical carcinosarcoma, migraine with or without aura, susceptibility to, cerebral infarction

#### Via Dasatinib (Similarity: 0.708)
- **Number of disease connections:** 8
- **Top diseases:** active peptic ulcer disease, heart failure, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, intracerebral hemorrhage, coronary thrombosis

#### Via Obinutuzumab (Similarity: 0.777)
- **Number of disease connections:** 2
- **Top diseases:** acute lymphoblastic/lymphocytic leukemia, Richter syndrome

#### Via Conjugated estrogens (Similarity: 0.756)
- **Number of disease connections:** 1
- **Top diseases:** psychologic dyspareunia


---

## Interpretation Guidelines

### How to Use This Report

1. **High-priority candidates:** Focus on paths with:
   - High attention scores (>0.6)
   - Short path length (2 hops)
   - Mechanistically plausible intermediate nodes

2. **Validation steps:**
   - Check if intermediate drugs share mechanism with Inebilizumab
   - Verify disease-gene associations in literature
   - Look for clinical evidence supporting the connection

3. **Risk assessment:**
   - Low attention scores (<0.5) indicate weaker evidence
   - Longer paths have more assumptions/uncertainty
   - Consider known side effects of similar drugs

### Attention Score Interpretation

| Score Range | Confidence Level | Interpretation |
|-------------|------------------|----------------|
| 0.70+ | â­â­â­â­â­ Very High | Strong biological relationship |
| 0.60-0.70 | â­â­â­â­ High | Good evidence for connection |
| 0.50-0.60 | â­â­â­ Medium | Moderate support |
| 0.40-0.50 | â­â­ Low | Weak connection |
| <0.40 | â­ Very Low | Speculative |

---

## About Inebilizumab's Mechanism

Inebilizumab (Uplizna) is a humanized monoclonal antibody that targets **CD19**, a protein found on the surface of B cells. Key points:

- **Target:** CD19 is expressed on B cells from early development through plasma cell differentiation
- **Mechanism:** Binds CD19 and triggers B cell depletion via ADCC
- **Effect:** Reduces B cell-mediated inflammation and autoimmunity
- **Current Use:** Approved for NMOSD, an autoimmune condition affecting the optic nerves and spinal cord

### Why Drug Similarity Paths Matter for Inebilizumab

Many of Inebilizumab's predicted paths go through other drugs because:

1. **Similar antibody drugs** (like Rituximab, which targets CD20) share the B-cell depletion mechanism
2. **Immunomodulatory drugs** (like Cladribine) affect similar immune cell populations
3. **Anti-inflammatory drugs** may have overlapping therapeutic applications

---

*Report generated from TxGNN Drug Explorer*
*Data source: PrimeKG Knowledge Graph + TxGNN Embeddings*
